Updated Agenda- CRISPR Congress in Berlin, 24-26 October 2016

Harnessing Precision Genome Editing Applications for Advanced Biomedical Research & Therapeutic Development

Tel: +44 (0)20 3141 8700 | Email: [email protected] CRISPR Precision Gene Editing

Researched & Developed By:www.crispr-europe.com

24th-26th October 2016 | Berlin, Germany

Lead Partner Additional Partners

Book now and save up to 4400

Bill Lundberg CRISPR Therapeutics

John FederBristol-Myers Squibb

Daniel Anderson MIT

John van der OostWageningen UR

Danilo Maddalo Novartis Institutes for BioMedical Research

Lennart Randau Max-Planck-Institute

1 1

3 3

2 2

4 4

5 5

Advance your understanding of CRISPR and Cas9 mechanisms to optimise downstream applications of precision gene-editing technology

Explore how Max-Planck are taking learnings from CRISPR/Cas structures and mechanisms in bacteria to identify target specificity

Develop optimised workflows to effectively integrate CRISPR technology into basic and biomedical research

Learn how Pfizer are integrating CRISPR technology for optimised target validation through CRISPR libraries

Integrate CRISPR technology in disease modelling and genome-wide screening to advance target identification and validation

Discover how Takeda Cambridge are developing customized designed IPS cells for in vitro disease modelling

Top 5 Key Takeaways Top 5 Ideas to Implement

Understand the regulatory environment for utilising CRISPR technology in crop breeding and take those learnings into your industry

Learn from Karolinska Institutet & Novartis on how to harness CRISPR-based genome-wide screening for optimised target identification

Harness precision gene engineering to develop cell-based therapies in oncology

Discover how Cellectis are clinically utilising TALENs to develop CAR-T therapies

Benefits of Attending

Tel: +44 (0)20 3141 8700 Email: [email protected]

www.crispr-europe.com

CRISPR & Precision Gene Editing Congress Europe Berlin, Germany | 24th-26th October 2016

CRISPR Precision Gene Editing

The Only Industry Congress Solely Dedicated to Optimising the Applications of CRISPR Precision Genome Editing in Europe

Develop your CRISPR workflows to power novel applications in target identification, disease modelling and therapeutic development

The CRISPR & Precision Genome Editing Congress Europe 2016 will continue to enhance and improve the very latest applications of CRISPR technology to pioneer basic research, biomedical research and therapeutic applications of precise genome engineering.

With customisation and optimisation of CRISPR design paramount, join leading biopharma and academic figureheads as they reveal advanced methodology, strategies and clinical timelines to fulfil the revolutionary promise of precision genome editing.

With beneficial applications of CRISPR increasing and alternative systems rapidly being developed, safeguard against future technical bottlenecks faced by early

adopters and new users alike by learning how to optimise CRISPR workflows to enhance the integration of precision gene editing within your research.

Discover how the industry is advancing the robustness of current applications of CRISPR including: disease modelling, target identification and validation, genome-wide screening and development of CRISPR therapeutics. Furthermore, as it establishes itself as the leading editing tool, discover future applications on the horizon.

In this truly innovative field, become part of the CRISPR Europe Congress in 2016 and join those dedicated to pioneering CRISPR/Cas9 to enhance applications in basic research to R&D productivity and revolutionise therapeutic development.





Expert Speaker Faculty Donald ApanovitchDirector, Functional Genomics & BiolomicsPfizer

Daniel AndersonSam Goldblith Associate ProfessorMIT

Bill LundbergChief Scientific OfficerCRISPR Therapeutics

Ross Kettleborough European Field Applications SpecialistTwist Bioscience

Danilo MaddaloLab Head, Oncology PharmacologyNovartis Institutes for BioMedical Research

Lennart RandauResearch Group Leader, Terrestrial MicrobiologyMax-Planck-Institute

John FederAssociate Director, Genome BiologyBristol-Myers Squibb

John van der OostProfessor, WU Agrotechnology & Food SciencesWageningen UR

Jonathan ChesnutSenior Director, Synthetic Biology R&DThermo Fisher Scientific

Evren AliciAssistant Professor & Research Group LeaderKarolinska Institutet

Roderick BeijersbergenGroup Leader, Division of Molecular Carcinogenesis & NKI Robotics & Screening CenterThe Netherlands Cancer Institute

Steve SheardownTransgenic Group HeadTakeda Cambridge

Laurent PoirotHead of Early DiscoveryCellectis

Emma ShanksHead of ScreeningThe Beatson Institute

Jennifer BermanStaff Scientist, Applications, Digital Biology CenterBio-Rad Laboratories

Kosuke Yusa Group Leader Wellcome Trust Sanger Institute

Alexander EspinosaAssistant ProfessorKarolinska Institutet

Niels GeijsenFounder & Scientific AdvisorNTrans

Petra JoraschVice Secretary GeneralGerman Plant Breeders’ Association

Beat SpäthDirector Agricultural BiotechnologyEuropaBio

Maria Celeste M. RamirezDirector of Product MarketingTwist Bioscience

Leigh BrodyDirector Genomic ServicesDesktop Genetics

Daniela HüberGene Modulation Specialist, DharmaconGE Healthcare

Speakers all gave excellent presentations - perfect

balance of both academic and industry viewpoints on leveraging CRISPR

technology. I enjoyed the format and structured networking sessions were

well thought out. I also appreciated the opportunity to connect with new experts

in this emerging field

Past Attendee, Warp Drive Bio

Pre-Conference Workshops, Monday 24th October 2016

Workshop A

Workshop B

I really enjoyed all the talks and the

variety in them, from pure academic to industrial

application. I thought the meeting was excellent

and well-worth it

Past Attendee, Broad Institute

I was able to get something out of

each presentation. It was a total success

in my opinion

Past Attendee, GlaxoSmithKline





One key application of CRISPR precision gene editing is in the discovery and functional understanding of genomics through high-throughput screening.

In this interactive workshop, you will capitalise lessons learned in order to:

• Optimise the implementation of CRISPR gene editing for target identification and validation

• Discuss technical strategies to improve CRISPR applications both in vitro and in vivo utilisation

• Harness protocols and strategies for large scale genome screens to develop CRISPR libraries

CRISPR/Cas9-mediated genome editing has become a rapidly adopted application in developing in vitro and in vivo preclinical models to better understand the complexity of human disease.

In this interactive workshop, you will discover solutions and answers to help you:

• Discover the impact of genome editing tools in preclinical investigation in industry

• Overcome the current limitations of using CRISPR for disease modelling

• Learn about and discuss case studies to standardise protocols to utilise CRISPR for in vitro and in vivo models

• Discover what information can we get from in vivo models

Enhancing CRISPR Technology for Target Identification and Developing Genome-Wide CRISPR Libraries within OncologyDate: Monday 24th October 2016 Time: 9.00-12.00

Developing More Physiologically-Relevant Disease Models With CRISPR for Improved Preclinical PredictabilityDate: Monday 24th October 2016 Time: 13.00-16.00

Danilo MaddaloLab Head, Oncology PharmacologyNovartis Institutes for BioMedical Research

Donald ApanovitchDirector, Functional Genomics & BiolomicsPfizer

About Your Workshop Leader:

At Memorial Sloan Kettering Cancer Center, Dr Maddalo established a model of chromosomal rearrangements using the CRISPR/Cas9 technology. Dr Maddalo, now at Novartis Institutes for Biomedical Research in Basel, focuses on mouse modelling of disease for drug discovery and target identification.

Very enjoyable and informative meeting.

The workshops at the beginning were

something new to me and I found them a very useful

means of idea sharing and networking

Past Attendee, Boehringer Ingelheim

About Your Workshop Leader:

Donald manages the Functional Genomics group in the Biolomics Department at Pfizer Research. The group is responsible for supporting the validation and/ or identification of new therapeutic targets across multiple therapeutic research areas using multiple high content imaging platforms and RNAi technologies.

Conference Day One, Tuesday 25th October 20168.00 Registration & Breakfast

9.00 Chairman’s Opening Remarks

Scalpel Precision: Empowering CRISPR to be Even More Precise

9.10 A CRISPR Screen Identifies Genetic Vulnerabilities in Acute Myeloid Leukaemia• Development and improvement of the CRISPR screening methodology for optimised

CRISPR workflows

• Applications of CRISPR gene editing for screening in oncology research

• Developing screening and libraries to identify genetic vulnerabilities in cancer cells

Ross Kettleborough, European Field Applications Specialist, TWIST Bioscience

Kosuke Yusa, Group Leader, Wellcome Trust Sanger Institute

9.40 Understanding the Mechanistic Actions of Cpf1 to Optimise Efficiency of CRISPR Precision Genome Editing • Addressing Cpf1 mechanisms and how it is currently being applied

• Comparing and contrasting the mechanisms of Cpf1 to Cas9

• What is the current efficiency readout for Cpf1 compared to Cas9?

John van der Oost, Professor, WU Agrotechnology & Food Sciences, Wageningen UR

10.10 Modulating the Architecture of Minimal Type I CRISPR-Cas Interference Complexes• Reviewing the landscape of highly divergent CRISPR-Cas systems

in prokaryotes

• Highlighting important structural and functional differences, which can impact target specificity

• Discussing the structural and targeting mechanisms, and the assembly of Cas protein interference complexes termed Cascade

Lennart Randau,Research Group Leader, Terrestrial Microbiology,Max-Planck-Institute

10.40 Speed Networking & Morning Refreshments

Improving Customised Design of CRISPR Workflows & Effective Data Analysis

11.40 Ultra-Sensitive Quantification of Genome Editing Events by Droplet Digital PCR• Development and optimisation of genome editing methods for a sensitive, rapid-readout

tool for edit validation and off-target detection

• Droplet Digital PCR (ddPCR) enables sensitive (<0.1%), precise absolute quantification of NHEJ and HDR alleles in a rapid, high-throughput format

Jennifer Berman, Staff Scientist, Applications, Digital Biology Center, Bio-Rad Laboratories

12.10 Transitioning From siRNA Screens to CRISPR Screens: Experiences From The Beatson Institute • Utilising high throughput functional genomics approaches with high content phenotypic

image analysis for target identification and validation across multiple cancer types using both immortal and primary cell cultures derived from patient tumours

• Transitioning from siRNA-based screens using both pooled and deconvolved approaches

• Exploring the value of adding CRISPR to our workflow as a screening tool by conducting i) genome-wide pooled sgRNA screens and ii) arrayed sgRNA phenotypic screens

• Comparative sgRNA and siRNA array evaluations using scalable cytotoxic, cytostatic and cell migration platforms

• Evaluations using our PhenoTox panel, containing targets generating apoptotic, autophagic, senescent, oxidative stress and ER stress phenotypes

Emma Shanks, Head of Screening, The Beatson Institute

12.40 CRISPR-Based Genome Editing Tools: New Applications & Improved Workflows• Streamline and high throughput CRISPR tool production

• Discussing improvements in gene knock-out and editing efficiency

• Evaluating new and efficient platforms for CRISPR-based functional genomics screening

Jonathan Chesnut, Senior Director, Synthetic Biology R&D, Thermo Fisher Scientific





13.10 Networking Lunch

Advancing Disease Modelling & Large Scale Genome-Wide Screening

14.10 Genome Editing Meets Mouse Modelling for Better Preclinical Tools• Highlighting the limitations of traditional mouse models

• Harnessing CRISPR for the precise development of physiologically relevant preclinical in vivo models

• Examples how genome editing as a tool has been utilised to generate better preclinical models

Danilo Maddalo, Lab Head, Oncology Pharmacology, Novartis Institutes for BioMedical Research

14.40 The Possibilities, Challenges & Success of CRISPR-Based Screening for Target Identification• Development and optimisation of screening models using CRISPR technology

• Selection of the best screening strategy

• Selection and follow-up of screening hits

Roderick Beijersbergen, Group Leader, Division of Molecular Carcinogenesis & NKI Robotics & Screening Center, The Netherlands Cancer Institute

15.10 Harnessing Fluorescent Properties of Small-Molecules for CRISPR/Cas9 Screens• Developing CRISPR screening protocols for target identification in oncology

• To harness the fluorescent properties of many anti-cancer drugs to identify unknown drug targets and to understand mechanisms of drug resistance

Alexander Espinosa, Assistant Professor, Karolinska Institutet

15.40 Afternoon Refreshments & Poster Competition Hosted by Twist BioscienceWith an agenda packed with case studies and data-driven presentations, the CRISPR Europe poster session will allow you deeper access into the most innovative research. Meet the scientists conducting exciting research and pick their brains to gain insights into the emerging CRISPR gene editing applications. Apply their learnings straight into your own work, cultivate research collaborations and leave inspired by new ideas.

16.25 Interactive CRISPR Roundtable DiscussionsIn this one hour session, you will have the opportunity to choose from four different topics and catch up on the latest advancements and learn from your fellow colleagues in this interactive format. The topics that will be discussed are the following:

17.25 Close of Day 1

17.30 Drinks Reception Hosted by Twist Bioscience

Ethics and impact CRISPR/Cas-9

for human germline editing

1. 2. 3. 4.Correcting

mutations in human genetic diseases

Preparing for clinical trials involving

therapies based on CRISPR-Cas9

Applications within genome editing

and transcriptome modulation





Conference Day Two, Wednesday 26th October 2016

7.30 Breakfast & Networking

8.30 Chairman’s Opening Remarks

Regulatory Landscape of CRISPR Across Industries

8.40 Panel Discussion: Navigating the Regulatory Environment for CRISPR as Novel Breeding TechniqueWith the advent of cheaper and faster gene sequencing technology and advanced genomics, precision gene editing provides an opportunity to add back useful characteristics by reintroducing some of the lost diversity in a more targeted manner to accelerate the breeding process.

As the agricultural industry will be leading the way in receiving regulatory approval to produce and market CRISPR edited crops and plants, what lessons learnt can other industries take from the regulatory process?

The panel will discuss and answer the following questions:• What opportunities do technologies like CRISPRs afford?

• What can be learned from the long history of safe use of random mutagenesis in the development of useful new crop characteristics?

• How will the method of deploying new technologies like CRISPRs affect the regulatory profile in plants and microbes?

• How might the outcomes achieved by new technologies like CRISPRs affect the regulatory profile in plants and microbes?

• What are the industry responsibilities?

Session Chair: Petra Jorasch, Vice Secretary General, German Plant Breeders’ Association

Beat Späth, Director Agricultural Biotechnology, EuropaBio

9.25 Keynote Session: Nucleic Acid Delivery Systems for RNA Therapy and Gene Editing• High throughput, combinatorial approaches have revolutionized small molecule drug discovery

• Here we describe our work on high throughput methods for developing and characterizing RNA delivery and gene editing systems

• Libraries of degradable polymers and lipid-like materials have been synthesized, formulated and screened for their ability to delivery RNA, both in vitro and in vivo

• A number of delivery formulations have been developed with in vivo efficacy, and show potential therapeutic application for the treatment of genetic disease, viral infection, and cancer

Daniel Anderson, Sam Goldblith Associate Professor, MIT

9.55 Morning Refreshments

Clinical Utility: Therapeutic Applications of CRISPR Gene Editing

10.25 Development and Optimisation of CRISPR Gene Editing for Drug Discovery Applications• Genome engineering is advancing at an incredible pace however applications across the types

of translational and predicative cell models now preferred for drug target discovery remains a challenge

• What areas of the drug discovery process will genome engineering have the biggest and most immediate impact?

• How does the pharmaceutical industry evaluate and implement a technology that is evolving so rapidly especially as it relates to the creation of genetic disease models in iPSCs?

John Feder, Associate Director, Genome Biology, Bristol-Myers Squibb





10.55 TALEN-Based Genome Editing for Adoptive T-Cell Therapies• Harnessing talen genome editing technology for clinical applications• Utilising talen-mediated genome editing in allogeneic T cells for adoptive immunotherapy• CAR T cell therapies will require genome editing to reach their full potential

Laurent Poirot, Head of Early Discovery, Cellectis

11.25 iTOP: A Novel Non-Viral Delivery System for Gene-Editing Based Therapeutics• Development of the iTOP technology, a proprietary platform technology for the intracellular delivery

of bioactive molecules• Highly efficient in vivo delivery of recombinant proteins• In vivo application in CRISPR-Cas9 mediated gene repair

Niels Geijsen, Founder & Scientific Advisor, NTrans

11.55 Bringing CRISPR Therapeutics into the Clinic • How are CRISPR gene editing approaches distinct from the older gene therapy or nuclease methods?• What important considerations need to be addressed as we bring CRISPR therapeutics into clinical

stage testing in patients?• Which therapeutic areas are currently being investigated using precision gene engineering? • What technical hurdles need resolving for successful clinical translation of CRISPR technology?

Bill Lundberg, Chief Scientific Officer, CRISPR Therapeutics

12.25 Networking LunchPioneering CRISPR in Drug Discovery & Target Identification

13.25 CRISPR-Cas9 Screening with Arrayed Synthetic crRNA Libraries• Discuss key factors for success with arrayed crRNA screening • Discover benefits of synthetic dual CRISPR guide RNA • Evaluate screening results using high content analysis with a cell cycle reporter line

Daniela Hüber, Gene Modulation Specialist, Dharmacon, GE Healthcare

13.55 Keynote Session: Strategies & Applications Using CRISPR and RNAi Technologies for Identification of Novel Oncology Druggable Targets• Genome editing approaches to accelerate drug discovery, target identification, validation & whole

genome screening• Genome editing technology could be employed as a screening tool for identifying or validating

potential cancer genes for therapeutic development

Donald Apanovitch, Director, Functional Genomics & Biolomics, Pfizer

14.40 Harnessing CRISPR Genome Editing for the Development of Cancer Immunotherapies • Highlighting protocol optimisation steps for CRISPR workflows • Addressing how CRISPR gene editing is being used in NK cells for oncology patient screening

Evren Alici, Assistant Professor & Research Group Leader, Karolinska Institutet

15.10 Enhancing the Takeda Cambridge Drug Discovery Toolkit with CRISPR/Cas9• How we use CRISPR to improve efficiency and remove bottlenecks in the rodent transgenic

production pipeline• Generating human-relevant models in vitro; our experiences using CRISPR/Cas9 to catalyse

somatic/iPS cell knockout and knockin, and the preferred strategies that we have adopted• Looking ahead, some thoughts on how we might improve reproducibility and confidence in in vitro

genome engineered systems

Steve Sheardown, Transgenic Group Head, Takeda Cambridge

15.40 Afternoon Refreshments

17.10 Chair’s Closing Remarks17.15 Close of CRISPR & Precision Genome Editing Congress Europe 2016

Reimagine CRISPR Workflows with Precision Guides From Design to Synthesis

16.10 Interactive Workshop Hosted by Twist BioscienceWith customisation and optimisation of CRISPR design paramount, learn how to optimise CRISPR workflows to enhance the integration of precision gene editing and down stream applications of CRISPR technology within your research.

In this interactive workshop, you will discover solutions and answers to help you:

• Overview on library design techniques for optimising CRISPR workflows

• Understand the impact of high quality DNA synthesis on enabling accurate editing

• Using specific examples of how these libraries are used in translational research to highlight the potential applications towards development of novel molecular therapeutics

Workshop Leaders: Leigh Brody, Director Genomic Services, Desktop Genetics Maria Celeste M. Ramirez, Director of Product Marketing, Twist Bioscience





Partners





Twist Bioscience

Our expertise is synthetic DNA. We have developed a manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools. Our platform overcomes the current inefficiencies of synthetic DNA production, and enables cost-effective, rapid and high-quality synthetic gene production. The Twist Bioscience platform has the potential to accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage.

www.twistbioscience.com

Lead Partner

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, our mission is

to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life Sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our four premier brands Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support.

www.thermoscientific.com

Programme Partner

Bio-Rad

Bio-Rad Laboratories, Inc. designs, manufactures, and distributes a

broad range of innovative tools and services to the life science research and clinical diagnostics markets. Founded in 1952, Bio-Rad has a global team of more than 7,750 employees and serves more than 100,000 research and industry customers worldwide through the company’s global network of operations. Throughout its existence, Bio-Rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, and medical diagnostics.

www.bio-rad.com

Programme Partner

Dharmacon – part of GE Healthcare

Dharmacon has revolutionized the field of RNA synthesis with the introduction of 2’-ACE synthesis chemistry since 1995. As leaders in custom RNA synthesis, Dharmacon was an early participant in the newly discovered field of RNA interference, and contributed several key scientific findings. Dharmacon RNAi products were some of the first commercially available.

In addition, Dharmacon offers a unique set of CRISPR-Cas9 gene editing tools. The Dharmacon CRISPR-Cas9 platform greatly simplifies the workflow of permanently knocking out genes.

www.dharmacon.gelifesciences.com

Programme PartnerCibus

Cibus is the leader in non-transgenic breeding & precision gene editing in agriculture. Our mission is to improve plants and other organisms with a new class of non-transgenic breeding technologies. These work without integrating foreign genetic material thus the resulting organisms are non-transgenic. Since our improvements are non-transgenic, they will be globally acceptable. The company has developed & patented advanced breeding technologies that enable precise, stable, predictable changes to be made in plants and other organisms without integrating foreign genetic material.

www.cibus.com

Programme Partner

Become a Partner:

Partnership Opportunities:

Contact

Diane McKenna Commercial Director, Genomics


As a result of the meeting we currently are involved in

active negotiations with three companies we met there and are in question-answering stage with others. Almost too much interest

for us to handle!

MD, Director, Washington University

School of Medicine

This meeting is designed to describe the profound impact

CRISPR is having on basic research and therapeutic

development. It explored the research tools, bioinformatics and expertise needed to make the most of this breakthrough

technology

Horizon





Merck

Merck Millipore and Sigma-Aldrich have come together as the life

science business of Merck KGaA, Darmstadt, Germany. With a portfolio spanning more than 300,000 products, including a diverse range of CRISPR reagents, whole genome screening libraries (including Sanger arrayed and GeCKO pooled libraries), validation services and technical expertise, our company is committed to solving the toughest problems in life science. For more information, visit:

www.merckmillipore.com

www.sigma-aldrich.com

ExhibitorNtrans

NTrans Technologies BV was founded in 2015 based on a

proprietary platform technology for the intracellular delivery of bioactive molecules developed at the Hubrecht Institute of the Royal Netherlands Academy of Sciences. The iTOP intracellular delivery technology is based on a combination of small molecule compounds which forces the uptake of large gulps of extracellular fluid (containing the bioactive molecules) by the cell. Once inside, the vesicles release their content into the cytoplasm, where the bioactive molecules can exert their therapeutic action. Our goal is to further support distribution and commercialization of the iTOP technology for the research community and to develop a therapeutic platform for iTOP based delivery of bioactive molecules. The NTrans mission is to translate the unique iTOP technology into revolutionary new therapies for the treatment of genetic diseases and cancer.

www.ntranstechnologies.com

The CRISPR & Precision Genome Editing Congress is a dedicated to enhance the very latest applications of CRISPR. This is where VPs, Directors and C-Level Executives from Pharma, Biotech and Academia are coming to search for the right partners.

This Congress enables the field to establish long term partnerships to secure future success. Network with new clients and cement existing relationships via speed networking, personal introductions and multiple industry-wide touch points.

There is no one size fits all approach to partnership at CRISPR Congress Europe 2016. When you work with us we will build a partnership that helps you achieve those aims.

Several opportunities exist to educate the industry on your product or service including speaking positions, exhibiting and hosting receptions. Demonstrate thought leadership, showcase expertise and educate the CRISPR community about your capabilities.

Programme Partner

* All discount offers (including team discounts) require payment at the time of registration to receive any discount. ‘Early Bird’ discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.

Register

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the four-teenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Terms & Conditions

Code: 6507

VAT will be charged at 19%

VAT will be charged at 19%

Pricing & VenueVenue

Pricing

I will certainly come back to the CRISPR

Congress. I have attended several conferences

about genome editing, but CRISPR Congress stands

out among them.Past Attendee

Standard Pricing Register & Pay before 30th September 2016

Standard Price*

Gold: Conference + 2 Workshops 23297 + VAT (Save 4400)

23497 + VAT (Save 4200)

Silver: Conference + 1 Workshop 22798 + VAT (Save 4300)

22998 + VAT (Save 4100)

Bronze: Conference Only 22299 + VAT (Save 4200)

22499 + VAT

Workshop (Each) 2599 + VAT

Academic Pricing Register & Pay before 30th September 2016

Standard Price*

Gold: Conference + 2 Workshops 21917 + VAT (Save 4300)

22017 + VAT (Save 4200)

Silver: Conference + 1 Workshop 21658 + VAT (Save 4200)

21758 + VAT (Save 4100)

Bronze: Conference Only 21399 + VAT (Save 4100)

21499 + VAT

Workshop (Each) 2359 + VAT





Hotel Palace BerlinBudapester, Str. 4510787, Berlin, GermanyAccommodation: Overnight accommodation is not included in the registration fee

www.crispr-europe.com/register Tel: +44 (0)20 3141 8700 Email: [email protected]

Mail: Hanson Wade 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU

• 10% discount – 3 delegates • 15% discount – 4 delegates • 20% discount – 5 or more delegatesPlease note that discounts are only valid when three or more delegates from one company book and pay at the same time.Team discounts cannot be applied to academic pricing.

Team Discounts*